Artificial intelligence-powered digital pathology model supports that fibrosis is reduced by semaglutide in patients with NASH

November 12, 2021

Study Background

Significantly greater number of primary endpoint responders is detected in treated vs. placebo arms by AIM-NASH but not manual AIM-NASH detected dose-dependent treatment response in Ph2 study, in addition a statistically significant difference in proportion of subjects achieving endpoints. Harrison et al.

View Poster

Get In Touch

PathAI Media

Company Contact

Liz Storti

Chief People Officer

elizabeth.storti@pathai.com

Media Contact

Daniel Donato

LifeSci Communications

ddonato@lifescicomms.com

516-474-0554